Associate Professor, Dell Medical School at The University of Texas at Austin
Internal stenting of the urinary tract may be pursued for maximal drainage (Desmond et al muscle relaxant pediatrics buy generic colospa 135 mg line, 1989) muscle relaxant yellow pill v order 135 mg colospa amex. Fistulae associated with a poorly functioning kidney are best treated by primary closure of the bowel and nephrectomy spasms quadriceps buy colospa discount. Case reports of ureterocolic fistulae occurring after renal cryotherapy and gunshot trauma all resolved with insertion of a ureteral stent (Vanderbrink et al muscle relaxant half-life order discount colospa, 2007; Ould Ismail et al, 2010). Rectal injury during radical prostatectomy occurs in less than 1% to 2% of patients (Igel et al, 1987; Borland and Walsh, 1992; McLaren et al, 1993; Guillonneau et al, 2003). Eleven of 13 injuries were recognized and repaired intraoperatively with a two-layer closure. One of these patients subsequently underwent temporary colostomy for complications related to the injury. Both patients with rectal injuries that were recognized postoperatively underwent colostomy. Nine of 10 patients had a two-layer closure performed with an omental interpositional flap at the time of injury. One patient underwent a temporary diverting colostomy; the rectal injury was diagnosed and repaired on postoperative day 2. Anal sphincter dilation was performed on all patients, and they received 7 to 14 days of postoperative antibiotics. Fistulae caused by Crohn disease are complex, and management should be individualized (Stamler et al, 1985; Fazio et al, 1987; Santoro et al, 1995; Cools et al, 1996; Rius et al, 2000). Digital rectal examination often permits palpation of the fistula tract along the anterior rectal wall. Cystoscopy and sigmoidoscopy (Shin et al, 2000) visualize the fistula tract in the vast majority of cases and provide a mechanism for biopsy. In patients with a history of pelvic malignancy, biopsy of the fistula is suggested to evaluate for a local recurrence Chapter89 UrinaryTractFistulae 2133 Figure 89-53. Lateral projections may be necessary to visualize small fistulae, because contrast in the rectum or urethra can sometimes obscure extremely thin fistulous tracts. The anorectal incision as described provides excellent exposure of the fistula in the anterior rectal wall. The fistula tract is excised, and the anterior rectal wall is mobilized circumferentially around the fistula margins. Closure of the incision is performed by reapproximating the posterior rectal wall and then sequentially closing the layers of the anal sphincter in an anatomic fashion. In the largest series of patients undergoing the York-Mason procedure, Renschler and Middleton (2003) reported a successful repair in 22 of 24 patients. One of the two failures was subsequently repaired with another York-Mason procedure. No serious complications were reported, and no patient developed anal incontinence or anal stenosis. Similar excellent results have been noted by other authors (Prasad et al, 1983; Bukowski et al, 1995; Fengler and Abcarian, 1997). The major disadvantage to this approach is the relatively poor exposure and lack of maneuverability within the operative field. Anatomically, this is a familiar approach for many urologists and has the added advantage of local access to a variety of potential interpositional flaps. Excellent results have been obtained with the perineal approach in combination with an interpositional flap, including gracilis muscle (Ryan et al, 1979; Rius et al, 2000; Zmora et al, 2003; Ghoniem et al, 2008; Gupta et al, 2008), pedicled Dartos muscle (Venable, 1989; Youssef et al, 1999; Yamazaki et al, 2001; Varma et al, 2007), penile skin (Morgan, 1975), levator muscle (Goodwin et al, 1958), and bladder (Kokotas and Kontogeorgos, 1983). The principal advantage of this technique is the availability of greater omentum for an interpositional flap. Potential disadvantages include the morbidity and prolonged postoperative convalescence associated with a laparotomy incision, poor exposure of the operative field (with limited maneuverability in the deep pelvis), and the risk of urinary and fecal incontinence. These fistulae may be large and are associated with considerable induration, fibrosis, and ischemia for a variable distance around the fistula, limiting reconstructive options. Urinary reconstruction may not be possible in some of these cases, necessitating urinary diversion. Three patients with satisfactory baseline continence underwent primary repair by a YorkMason approach with a gracilis flap; 7 patients underwent urinary diversion combined with radical pelvic surgery (6 cystoprostatectomy, 1 prostatectomy); and 1 refused repair. Additional procedures may be needed to bring about a satisfactory result in these patients; this is an important issue to discuss in preoperative patient counseling. Successful closure in 6 patients eventually was accomplished with a transanal Latzko procedure (see later). Successful minimally invasive management has been reported, as well, with use of endoscopic suturing, fulguration of the fistula tract, and the application of fibrin glue (Wilbert et al, 1996). The controversy surrounding the staged repair centers on the issue of whether or not to perform fecal diversion at all, or whether to perform it before or at the time of repair of the urinary tract. This is considered the standard conservative approach and, in combination with an indwelling urethral catheter, permits a trial of spontaneous healing of the fistula without open manipulation of the urinary tract. In support of the single-stage repair, a successful one-stage approach limits the potential morbidity and cost of multiple procedures that, by design, accompany the staged repair. Staged repairs might be considered in cases of large fistulae, those associated with radiation therapy, uncontrolled local or systemic infection, immunocompromised states, or inadequate bowel preparation at the time of definitive repair (Stephenson and Middleton, 1996; NunooMensah et al, 2008). The York-Mason procedure is a transrectal, transsphincteric approach that has been found to be effective and to have low morbidity (Henderson et al, 1981; Prasad et al, 1983; Wood and Middleton, 1990; Stephenson and Middleton, 1996; Fengler and Abcarian, 1997; Renschler and Middleton, 2003). However, in patients with small, nonirradiated fistulae, a singlestage approach can be used, provided that a vigorous bowel preparation and broad-spectrum antibiotics are used (Renschler and Middleton, 2003). For repair of the urinary tract, the patient is placed prone on the operating room table in the jackknife position. A full-thickness incision through the posterior anus and dorsal rectal wall is performed and deepened down to the level of the coccyx through the external anal sphincter. Later in the procedure during closure, careful anatomic Incision Chapter89 UrinaryTractFistulae 2135 Coccyx Posterior rectal wall Fistula Anterior rectal wall Internal sphincter muscle External sphincter muscle Figure 89-55.
By week 12 muscle relaxant before massage buy colospa 135 mg mastercard, trospium significantly decreased average frequency of toilet voids per 24 hours (-2 spasms 14 year old beagle buy discount colospa 135 mg online. At study end muscle relaxer sleep aid buy colospa now, there were no relevant differences between the "dose adjustment" subgroups and the respective "no dose adjustment" subgroups (trospium muscle relaxant erowid cheap colospa 135 mg visa, P =. After dose escalation, worsening of dry mouth was higher in both dose-adjusted subgroups compared with the respective "no dose adjustment" subgroups (P <. They all have a more-orless pronounced antimuscarinic effect and, in addition, an often poorly defined "direct" action on bladder muscle. For several of these drugs, the antimuscarinic effects can be demonstrated at much lower drug concentrations than the direct action, which may involve blockade of voltage-operated Ca2+ channels. Most probably, the clinical effects of these drugs can be explained mainly by an antimuscarinic action. Among the drugs with mixed actions was terodiline, which was withdrawn from the market because it was suspected to cause polymorphic ventricular tachycardia (torsades de pointes) in some patients (Connolly et al, 1991; Stewart et al, 1992). The primary metabolite, N-desethyloxybutynin, has pharmacologic properties similar to those of the parent compound (Waldeck et al, 1997) but occurs in much higher concentrations after oral administration (Hughes et al, 1992). It has been implicated as the major cause of the troublesome side effect of dry mouth associated with the administration of oxybutynin. It seems reasonable to assume that the effect of oral oxybutynin to a large extent is exerted by the metabolite. The occurrence of an active metabolite may also explain the lack of correlation between plasma concentration of oxybutynin itself and side effects in geriatric patients reported by Ouslander and colleagues (1988). The plasma half-life of the oxybutynin is approximately 2 hours, but with wide interindividual variation (Douchamps et al, 1988; Hughes et al, 1992). It has both an antimuscarinic and a direct muscle relaxant effect, and, in addition, local anesthetic actions. The latter may be of importance when the drug is administered intravesically, but probably play no role when it is given orally. In vitro, oxybutynin was 500 times weaker as a smooth muscle relaxant than as an antimuscarinic agent (Kachur et al, 1988). Most probably, when given systemically, oxybutynin acts mainly as an antimuscarinic drug. Oxybutynin has a high affinity for muscarinic receptors in human bladder tissue and effectively blocks carbachol-induced contractions (Nilvebrant and Sparf, 1988; Waldeck et al, 1997). The drug was shown to have slightly higher affinity for muscarinic M1 and M3 receptors than for M2 receptors (Nilvebrant and Sparf, 1986; Norhona-Blob and Kachur, 1991), but the clinical significance of this is unclear. Some of the available formulations of oxybutynin were overviewed by McCrery and Appell (2006). The mean decrease in incontinence was recorded as 52% and the mean reduction in frequency per 24 hours was 33% (data on placebo not presented). The overall "subjective improvement" rate was reported as 74% (range 61% to 100%). The mean percent of patients reporting an adverse effect was 70% (range 17% to 93%). In this study, patient compliance was 97% and side effects, mainly dry mouth, were reported by only 8% of the patients (Amarenco et al, 1998). In 75 nursing home residents, Ouslander and colleagues (1995) found that oxybutynin did not add to the clinical effectiveness of prompted voiding in a placebo-controlled, double-blind, crossover trial. Several open studies in patients with spinal cord injuries suggested that oxybutynin, given orally or intravesically, can be of therapeutic benefit (Kim et al, 1996; Szollar and Lee, 1996). These are typically antimuscarinic in nature (dry mouth, constipation, drowsiness, blurred vision) and are often dose limiting (Baigrie et al, 1988; Jonville et al, 1992). The formulation uses an osmotic system to release the drug at a controlled rate over 24 hours distally primarily into the large intestine where absorption is not subject to first-pass metabolism in the liver. Dose titrations began at 5 mg, and the dose was increased every 4 to 7 days until one of three end points was achieved. A negative aspect of these studies is that there were no naive patients included; all patients were known responders to oxybutynin. The dose for each patient was adjusted after discussions of efficacy and tolerability between doctor and patient, over a 12-week treatment period. Several studies have documented the possibility that oxybutynin may have negative effects on cognitive functions, particularly in the elderly population but also in children (see. Despite the adverse effect profile, it is still an established therapeutic option. Several aspects of the preclinical, pharmacokinetic, and clinical effects of propiverine have been reviewed by Madersbacher and Murz (2001). The drug is rapidly absorbed (Tmax 2 hours) but has a high first-pass metabolism, and its biologic availability is about 50%. Propiverine is an inducer of hepatic cytochrome P450 enzymes in rats in doses about 100 times above the therapeutic doses in humans (Walter et al, 2003).
Dantrolene exerts its effects by a direct peripheral action on skeletal muscle (Standaert and Young spasms pelvic area discount 135 mg colospa with mastercard, 2006; Taylor muscle relaxant reversals purchase genuine colospa, 2006) spasms brain purchase cheap colospa. It is thought to inhibit the excitation-induced release of calcium ions from the sarcoplasmic reticulum of striated muscle fibers muscle relaxant pain reliever purchase 135mg colospa mastercard, thereby inhibiting excitation-contraction coupling and diminishing the mechanical force of contraction. The blockade of calcium release is not complete, however, and contraction is not completely abolished. It reduces reflex more than voluntary contraction, probably because of a preferential action on fast-type, as compared with slow-type, skeletal muscle fibers. The drug has been reported to improve voiding function in some patients with classic detrusor striated sphincter dyssynergia and was initially reported as being very successful in doing so (Murdock et al, 1976). Therapy in adults is recommended to begin at a dose of 25 mg daily, and this is gradually increased by increments of 25 mg every 4 to 7 days to a maximal oral dose of 400 mg given in four divided doses. Hackler and coworkers (1980) achieved improvement in voiding function in approximately half of their patients treated with dantrolene but found that such improvement required oral doses of 600 mg daily. Although no inhibitory effect on bladder smooth muscle seems to occur (Harris and Benson, 1980), the generalized weakness that dantrolene can induce is often significant enough to compromise its therapeutic effects. Other potential side effects include euphoria, dizziness, diarrhea, and hepatotoxicity. The risk of hepatic injury is twofold greater in female patients (Ward et al, 1986). One agreed-on use of dantrolene is to acutely manage malignant hyperthermia, a rare hereditary syndrome characterized by vigorous contraction of skeletal muscle precipitated by excess release of calcium from the sarcoplasmic reticulum, usually in response to neuromuscular blocking agents or inhalational anesthetics. Virtually no one currently uses dantrolene for the treatment of voiding dysfunction. It is interesting that it produces enough weakness of the muscle to prevent or considerably ameliorate spasm or involuntary contraction but not to completely block voluntary control, a phenomenon hypothesized to occur because more active neuromuscular junctions are more likely than less active junctions to be blocked by the effect of the drug (Hallett, 1999). Its urologic use for the treatment of detrusor striated sphincter dyssynergia was first reported by Dykstra and colleagues (Dykstra and Sidi, 1990; Dykstra et al, 1998, 2003). Injections were carried out weekly for 3 weeks, achieving a duration of effect averaging 2 1874. Although a long way from clinical use, nicotinic receptors in the striated sphincter have been shown to be a potential target for drug therapy for striated sphincter dyssynergia. Theoretically, any agent that promotes striated sphincter relaxation in a uroselective manner could be used to decrease outlet resistance and facilitate voiding dysfunction. The drug is a toxin Chapter79 PharmacologicManagementofLowerUrinaryTractStorageandEmptyingFailure 1874. New roles for muscarinic receptors in the pathophysiology of lower urinary tract symptoms. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. Treatment-resistant detrusor overactivity-underlying pharmacology and potential mechanisms. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Effects of prazosin on isolated human urethra and in patients with lower motor neurons lesions. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Pharmacologic treatment of bladder hyperactivity after augmentation and substitution enterocystoplasty. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. The l-arginine/nitric oxide pathway and nonadrenergic, non-cholinergic relaxation of the lower urinary tract. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. Pharmacology of the lower urinary tract-basis for current and future treatments of urinary incontinence. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Effects of mirabegron, a novel beta3adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction. What is the available evidence for hormone replacement therapy in women with stress urinary incontinence Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. Trospium chloride (Spasmolyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomised, nulticentre, placebo-controlled study. Failure of monotherapy in primary monosymptomatic enuresis: a combined desmopressin and propiverine treatment regimen improves efficacy outcomes. Desmopressin treatment regimens in monosymptomatic and nonmonosymptomatic enuresis: a review from a clinical perspective. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based
Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype spasms from kidney stones buy colospa 135 mg without a prescription. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study spasms coughing order line colospa. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder muscle relaxant use in elderly purchase colospa 135mg overnight delivery. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms spasms verb purchase 135 mg colospa amex. Urodynamics and management of the neuropathic bladder in spinal cord injury patients. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients Cannabinoid receptor2 is increased in acutely and chronically inflamed bladder of rats. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the Chapter79 PharmacologicManagementofLowerUrinaryTractStorageandEmptyingFailure 1874. Systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Systematic review and metaanalysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. Effects of tadalafil on nighttime voiding (nocturia) in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a post hoc analysis of pooled data from four randomized, placebo-controlled clinical studies. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects. Absolute bioavailability of imidafenacin after oral administration to healthy subjects. Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or =50 years. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents Report of a double-blind crossover study of flurbiprofen and placebo in detrusor instability. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. Treatment disorders of bowel motility and water flux; antiemetics; agents used in biliary and pancreatic disease. Drug insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Effects of tiagabine, a gamma-aminobutyric acid re-uptake inhibitor, on normal rat bladder function. Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. A randomized crossover study to evaluate Ro 115-1240, a selective alpha1 A/1L-adrenoceptor partial agonist in women with stress urinary incontinence. A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence. Impact of nocturia on bone fractures and mortality in older people: a Japanese longitudinal cohort study. Tolterodine and imipramine in refractory enuresis: a placebo-controlled crossover study. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. Dicyclomine, benzhexol and oxybutynin distinguish between subclasses of muscarinic binding sites. Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor. Botulinum toxin for the treatment of idiopathic and neurogenic overactive bladder: state of the art. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
